GlassScriptPhysician profile
Tai N Nguyen
NPI 1982659629
$3,727.64
in general payments reported to CMS, 2019-2025
29 companies · $619 in 2025
The $619 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $442 · 2021: $636 · 2022: $719 · 2023: $391 · 2024: $265 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $1,209.76 | 2019-2023 | |
| Pfizer INC. | $303.06 | 2019-2025 | |
| Gilead Sciences, INC. | $301.14 | 2021-2023 | |
| Lilly USA, LLC | $249.79 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $214.10 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $153.09 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $145.13 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $139.06 | 2021-2025 | |
| Glaxosmithkline, LLC. | $130.41 | 2020-2024 | Arexvy, Shingrix |
| Abbott Laboratories | $122.73 | 2021-2022 | |
| Esperion Therapeutics, INC. | $112.63 | 2021-2025 | Nexletol |
| Amgen INC. | $97.15 | 2019-2025 | Repatha, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $89.28 | 2023-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $84.80 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.69 | 2021-2025 | Xifaxan |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $42.12 | 2022 | |
| Inspire Medical Systems, INC. | $36.84 | 2024-2025 | Inspire |
| Exact Sciences Corporation | $34.18 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $33.19 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.59 | 2019-2021 | |
| Allergan, INC. | $24.63 | 2019 | |
| Livanova USA, INC. | $23.61 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Seqirus USA INC | $22.22 | 2025 | Flucelvax, Fluad |
| Kiniksa Pharmaceuticals, LTD. | $18.87 | 2023 | Arcalyst |
| Nestle Healthcare Nutrition INC. | $15.20 | 2022 | |
| Astellas Pharma US INC | $14.56 | 2025 | Veozah |
| Novo Nordisk INC | $14.21 | 2020 | |
| Azurity Pharmaceuticals, INC. | $13.80 | 2025 | Alvesco |
| Althera Pharmaceuticals LLC | $5.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tai Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.